Standard Operating Procedure for Inline UV Absorbance Monitoring in Biosimilar Manufacturing

1. Purpose

To define a GMP-compliant procedure for operating, calibrating, and maintaining inline UV absorbance sensors used for monitoring biosimilar protein concentration during chromatography and ultrafiltration processes.

2. Scope

This SOP applies to all inline UV detectors integrated with chromatography skids, TFF systems, and UF/DF units within biosimilar downstream purification operations.

3. Responsibilities

• Manufacturing: Operate and monitor inline UV systems during batch processing.
• Engineering: Calibrate and maintain UV sensors as per schedule.
• QA: Review UV absorbance data logs and deviations; verify calibration certificates.

4. Accountability

The Head of Manufacturing and Head of Engineering are accountable for ensuring the integrity and accuracy of inline UV absorbance monitoring systems.

5. Procedure

5.1 System Preparation and Verification

1. Ensure the UV detector is powered and connected to the skid HMI or SCADA interface.
2. Check that the correct wavelength (typically 280 nm for protein detection) is selected.
3. Verify that the system baseline is stable before starting the purification run.

5.2 Calibration and Standardization

1. Perform calibration using potassium dichromate standards at specified concentrations (Annexure-1).
2. Record absorbance values at 280 nm and validate linearity across the range (e.g., 0.1 to 2.0 AU).
3. Calibrate annually or as per manufacturer recommendation.
4. Document all calibration activity in Annexure-2.

5.3 Inline Monitoring During Operation

1. During chromatography or filtration, monitor the UV signal continuously.
2. Use UV trace to identify:
   • Peak elution windows
   • Breakthrough detection
   • End-of-run indication
3. Capture data in real-time using integrated data acquisition systems.
4. Compare peak profiles with batch standards to detect anomalies.

5.4 Signal Threshold and Trigger Points

1. Set UV absorbance thresholds in skid automation (e.g., 0.1 AU for elution start, 0.05 AU for elution end).
2. Ensure operator is trained on modifying or acknowledging UV-based triggers for fraction collection.
3. Confirm fractionation valves respond to UV threshold accurately.

5.5 Data Logging and Batch Record Entry

1. Ensure continuous UV data is logged in electronic batch record or SCADA system.
2. Export absorbance curves for archiving and review.
3. Log any deviation from expected UV pattern in Annexure-3.

5.6 Maintenance and Cleaning

1. Flush UV flow cell with WFI post-batch.
2. Use 0.1 M NaOH for weekly sanitization, followed by neutralization and rinse.
3. Inspect quartz cell for fouling or damage every month and clean if needed.

5.7 Deviation Handling

1. In case of signal loss, drift, or non-linearity:
   • Pause operation if required
   • Document incident (Annexure-3)
   • Switch to offline UV confirmation for critical process points

6. Abbreviations

• AU: Absorbance Unit
• UV: Ultraviolet
• SCADA: Supervisory Control and Data Acquisition
• WFI: Water for Injection

7. Documents

1. UV Calibration Standards Log – Annexure-1
2. UV Calibration Record – Annexure-2
3. UV Deviation Log – Annexure-3

8. References

• ICH Q8 – Pharmaceutical Development
• PDA TR 13 – Fundamentals of UV Monitoring in Biotech Processing
• FDA Guidance on PAT (Process Analytical Technology)

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: UV Calibration Standards Log

Annexure-2: UV Calibration Record

Annexure-3: UV Deviation Log

Revision History:

Standard Operating Procedure for Resin Performance Qualification in Biosimilar Manufacturing

1. Purpose

To establish a validated and GMP-compliant procedure for qualifying the performance of chromatography resins used in biosimilar purification processes, including assessment of binding capacity, leakage, pressure-flow characteristics, and resin longevity.

2. Scope

This SOP applies to all resins used in protein A, ion-exchange (IEX), hydrophobic interaction chromatography (HIC), and size exclusion chromatography (SEC) operations in downstream processing of biosimilars.

3. Responsibilities

• Process Development: Define performance specifications and sampling plan.
• Production: Execute purification runs and collect samples for analysis.
• QC: Perform analytical testing of collected fractions (titer, HCP, DNA, leakage).
• QA: Review qualification data and approve resin use beyond initial lifecycle.

4. Accountability

The Head of Manufacturing and Head of Quality Control are accountable for the implementation and lifecycle qualification of chromatography resins in accordance with GMP standards.

5. Procedure

5.1 Resin Selection and Documentation

1. Ensure all chromatography resins are purchased from approved vendors with CoA and MSDS.
2. Record resin lot number, batch number, manufacturer, and expiry in Annexure-1.

5.2 Initial Qualification (Baseline Run)

1. Pack the chromatography column as per validated protocol.
2. Perform a standard purification cycle using qualified bulk material.
3. Measure and record:
   • Dynamic binding capacity (DBC) at 10% breakthrough
   • Recovery yield (%)
   • Pressure vs. flow rate profile
   • Leakage of ligand or protein A (Annexure-2)

5.3 Periodic Qualification (Usage-Based)

1. At defined intervals (e.g., every 10 cycles), repeat DBC and leakage testing.
2. Monitor changes in pressure-flow behavior and compare with baseline.
3. Document results in Resin Qualification Log (Annexure-3).

5.4 Acceptance Criteria

1. DBC should not decrease by more than 20% from initial value.
2. Ligand leakage (e.g., protein A) must remain within qualified limits (e.g., <10 ppm).
3. Flow rate at standard pressure must not fall below 80% of baseline.

5.5 Resin Cleaning and Storage

1. Clean resin using vendor-recommended protocol (e.g., 0.1 M NaOH for Protein A).
2. Store resin in validated storage buffer at 2–8°C, protected from light.

5.6 Requalification or Discontinuation

1. If any parameter exceeds acceptance criteria, perform root cause analysis (Annexure-4).
2. Resin may be:
   • Requalified after additional cleaning and retesting
   • Discarded if unfit for further use
3. Update resin inventory and lifecycle usage records.

6. Abbreviations

• DBC: Dynamic Binding Capacity
• HCP: Host Cell Protein
• CoA: Certificate of Analysis
• MSDS: Material Safety Data Sheet

7. Documents

1. Resin Receipt and Tracking Log – Annexure-1
2. Baseline Qualification Report – Annexure-2
3. Resin Performance Log – Annexure-3
4. Root Cause and Requalification Record – Annexure-4

8. References

• ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
• PDA TR No. 60 – Process Validation: A Lifecycle Approach
• Resin vendor product monographs and technical bulletins

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Resin Receipt and Tracking Log

Annexure-2: Baseline Qualification Report

Annexure-3: Resin Performance Log

Annexure-4: Root Cause and Requalification Record

Revision History:

Standard Operating Procedure for Chromatography Skid Calibration in Biosimilar Manufacturing

1. Purpose

To establish a standardized procedure for the calibration of chromatography skid systems used in biosimilar downstream processing to ensure all critical sensors and control instruments meet GMP calibration requirements.

2. Scope

This SOP applies to all chromatography skids used in biosimilar purification processes including Protein A, ion-exchange, HIC, and polishing columns in GMP manufacturing areas.

3. Responsibilities

• Engineering: Perform calibration of instrumentation as per schedule.
• Production: Support in providing access to skids and verifying results.
• QA: Review calibration certificates, approve deviations, and control calibration schedules.

4. Accountability

The Head of Engineering and Head of Quality Assurance are accountable for ensuring that all chromatography skids are calibrated and maintained in validated condition.

5. Procedure

5.1 Preparation

1. Refer to the calibration master plan and verify due dates for chromatography skids.
2. Ensure equipment is shut down, depressurized, and LOTO (Lockout Tagout) is applied.
3. Gather certified reference standards and tools:
   • Flow standard (e.g., gravimetric setup)
   • Pressure calibrator
   • Conductivity and pH standard solutions
   • UV photometer calibrator

5.2 Calibration of Flow Sensor

1. Use a calibrated flow standard to simulate flow through skid pump line.
2. Compare displayed value with actual flow and adjust calibration factor if deviation exceeds ±5%.
3. Document results in Annexure-1.

5.3 Calibration of Pressure Transducers

1. Use a pressure calibrator to apply known pressure points (e.g., 0, 1, 2, 3 bar).
2. Check sensor output and ensure linearity across range.
3. Record all readings in Annexure-2. Acceptable deviation: ±1% of full scale.

5.4 pH and Conductivity Sensor Calibration

1. Disconnect in-line sensors and immerse in certified standard solutions (pH 4.0, 7.0, and 10.0).
2. Calibrate conductivity sensors using standards at 1.3 and 5.0 mS/cm.
3. Perform calibration through system HMI or local controller. Record in Annexure-3.

5.5 UV Detector Calibration

1. Run potassium dichromate solution or use a filter photometer to validate 280 nm absorbance accuracy.
2. Compare with reference standard. Acceptable deviation: ±0.005 AU.
3. Record findings in Annexure-4.

5.6 Calibration Labeling and Documentation

1. Affix calibration status label on each calibrated component with:
   • Calibration date
   • Due date
   • Technician initials
2. Update equipment history sheet and calibration tracking system.

5.7 Out-of-Tolerance (OOT) Handling

1. If sensor readings fall outside acceptance limits:
   • Tag as “Calibration Failed”
   • Notify QA and initiate deviation (Annexure-5)
   • Investigate potential impact on batches processed since last valid calibration

6. Abbreviations

• HIC: Hydrophobic Interaction Chromatography
• pH: Power of Hydrogen
• UV: Ultraviolet
• OOT: Out of Tolerance

7. Documents

1. Flow Sensor Calibration Log – Annexure-1
2. Pressure Sensor Calibration Log – Annexure-2
3. pH/Conductivity Sensor Log – Annexure-3
4. UV Calibration Report – Annexure-4
5. OOT Report – Annexure-5

8. References

• GAMP 5 – Good Automated Manufacturing Practice
• ICH Q10 – Pharmaceutical Quality System
• WHO TRS 961 – GMP for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Flow Sensor Calibration Log

Annexure-2: Pressure Sensor Calibration Log

Annexure-3: pH/Conductivity Sensor Log

Annexure-4: UV Calibration Report

Annexure-5: OOT Report

Revision History:

Standard Operating Procedure for Deviation Handling in Downstream Processing (DSP) in Biosimilar Manufacturing

1. Purpose

To define a systematic and GMP-compliant approach for identifying, documenting, investigating, and resolving deviations observed during downstream processing (DSP) of biosimilar drug substances.

2. Scope

This SOP applies to all deviations encountered during DSP activities such as chromatography, filtration, buffer preparation, bulk storage, and equipment operations within biosimilar manufacturing facilities.

3. Responsibilities

• Process Operators: Immediately report any deviation or abnormality observed during DSP operations.
• Manufacturing Supervisor: Document the deviation, initiate preliminary impact assessment, and notify QA.
• QA: Lead the deviation investigation, assign root cause analysis (RCA), approve CAPA, and ensure closure.
• Department Head: Approve investigation summary and assess need for process requalification if applicable.

4. Accountability

The Head of Quality Assurance is accountable for ensuring that all DSP-related deviations are addressed in a timely, documented, and compliant manner as per GMP and regulatory standards.

5. Procedure

5.1 Identification and Initial Reporting

1. Operators must report any unexpected event, parameter deviation, or equipment malfunction during DSP activities.
2. Examples include:
   • Chromatography pressure spikes
   • Filter integrity failure
   • Buffer pH out of range
   • Equipment alarms or unplanned shutdowns
3. Record initial details in the Deviation Form (Annexure-1) and notify the supervisor and QA.

5.2 Documentation and Categorization

1. Assign deviation number and classify as:
   • Minor: No direct impact on product or process
   • Major: Potential impact on product/process but controlled
   • Critical: Confirmed impact on product quality, safety, or regulatory compliance
2. Enter deviation in the Deviation Register (Annexure-2).

5.3 Investigation and Root Cause Analysis

1. Form cross-functional team including QA, Production, and Engineering to perform RCA.
2. Use Fishbone, 5-Why, or FMEA tools to identify root cause.
3. Document investigation report, evidence, and interviews in Annexure-3.

5.4 CAPA Implementation

1. Define Corrective Actions to fix the immediate issue (e.g., retraining, equipment repair).
2. Define Preventive Actions to prevent recurrence (e.g., SOP revision, parameter tightening).
3. Assign responsibility and timeline. QA to verify CAPA effectiveness after implementation.

5.5 Product Impact and Disposition

1. Assess product impact in consultation with QA, QC, and regulatory affairs.
2. Batch may be:
   • Accepted with justification
   • Reprocessed (if permitted)
   • Rejected and disposed
3. Document final disposition in the Batch Manufacturing Record (BMR).

5.6 Deviation Closure

1. QA ensures all investigation steps, CAPA actions, and approvals are complete.
2. Update Deviation Register and archive records for minimum 5 years.

6. Abbreviations

• DSP: Downstream Processing
• CAPA: Corrective and Preventive Action
• QA: Quality Assurance
• BMR: Batch Manufacturing Record

7. Documents

1. Deviation Reporting Form – Annexure-1
2. DSP Deviation Register – Annexure-2
3. Investigation and RCA Template – Annexure-3

8. References

• ICH Q9 – Quality Risk Management
• EU GMP Chapter 1 – Pharmaceutical Quality System
• FDA QMS Guidelines for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Deviation Reporting Form

Annexure-2: DSP Deviation Register

Annexure-3: Investigation and RCA Template

Revision History:

Standard Operating Procedure for Environmental Monitoring During Purification in Biosimilar Manufacturing

1. Purpose

To establish a comprehensive and GMP-compliant procedure for environmental monitoring (EM) during the purification processes in biosimilar manufacturing to detect microbial and particulate contamination in controlled areas.

2. Scope

This SOP applies to viable and non-viable monitoring activities carried out in Grade B and C areas where biosimilar purification activities are conducted, including chromatography, filtration, and hold steps.

3. Responsibilities

• Microbiology/EM Analyst: Perform sampling, incubation, and data recording for all EM parameters.
• Production: Support coordination during operation-based sampling and report any abnormal conditions.
• QA: Review EM data, approve trend reports, and take decisions in case of alert/action level excursions.

4. Accountability

The Head of Microbiology is accountable for implementation and evaluation of the EM program to ensure environmental control during downstream biosimilar processing.

5. Procedure

5.1 EM Sampling Plan

1. Define EM plan based on risk assessment of purification activities and classified areas.
2. Include sampling points for:
   • Airborne viable count (settle plates and active air sampling)
   • Non-viable particulate monitoring (0.5 µm and 5.0 µm)
   • Surface monitoring (contact plates/swabs)
   • Personnel monitoring (gloves, gown)
3. Frequency: Daily (critical steps), weekly (routine), and per batch (process monitoring).

5.2 Viable Monitoring

1. Expose settle plates for 4 hours at critical sites such as chromatography skids, filtration units.
2. Use portable active air sampler calibrated for 1,000 L of air; position near operator workstation and process area.
3. Perform contact plate sampling on cleaned surfaces post-operation (Annexure-1).
4. Incubation conditions:
   • 30–35°C for 3–5 days
   • 20–25°C for 5–7 days

5.3 Non-Viable Monitoring

1. Use calibrated particle counter during operations to monitor 0.5 µm and 5.0 µm particles.
2. Monitor during filtration, bulk transfer, and other critical open operations.
3. Log particle count results in Annexure-2. Ensure compliance with ISO Class 7/8 limits as applicable.

5.4 Personnel Monitoring

1. Collect fingertip and gown surface samples from operators at end of operation.
2. Record results and compare with limits:
   • Fingertip: ≤ 10 cfu/glove
   • Gown surface: ≤ 5 cfu/plate
3. Deviations must be investigated (Annexure-3).

5.5 Alert and Action Limits

1. Establish limits based on area classification and historical trending.
2. If alert limit is breached: monitor additional samples and initiate alert notification.
3. If action limit is breached: quarantine product, initiate deviation/CAPA, and investigate root cause.

5.6 Trend Analysis and Reporting

1. Monthly EM trend reports to be prepared and reviewed by QA and Microbiology.
2. Identify upward trends, repeat observations, and seasonal variation.
3. Submit to QA for periodic review and regulatory compliance.

6. Abbreviations

• EM: Environmental Monitoring
• cfu: Colony Forming Unit
• QA: Quality Assurance
• CAPA: Corrective and Preventive Action

7. Documents

1. Surface Monitoring Log – Annexure-1
2. Non-Viable Particulate Log – Annexure-2
3. EM Deviation Report – Annexure-3

8. References

• EU GMP Annex 1 – Manufacture of Sterile Medicinal Products
• ISO 14644 – Cleanroom Classification Standards
• WHO TRS 961 – GMP for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Surface Monitoring Log

Annexure-2: Non-Viable Particulate Log

Annexure-3: EM Deviation Report

Revision History:

Standard Operating Procedure for Filter Sterilization of Final Bulk in Biosimilar Manufacturing

1. Purpose

To define the GMP-compliant procedure for filter sterilization of final biosimilar bulk drug substance using validated 0.22 µm filters to ensure microbial safety prior to formulation or fill-finish operations.

2. Scope

This SOP applies to all biosimilar final bulk drug substances intended for sterile formulation, where final sterile filtration is the last step before release or fill-finish transfer.

3. Responsibilities

• Production: Perform sterile filtration using validated equipment and handle product aseptically.
• QA: Review sterilization batch records, filter integrity tests, and approve batch release.
• Engineering: Maintain filtration skids, perform calibration of integrity testers, and support troubleshooting.

4. Accountability

The Head of Manufacturing is accountable for ensuring that filter sterilization is carried out under validated and aseptic conditions, and that integrity testing is performed before and after filtration.

5. Procedure

5.1 Preparation and Setup

1. Verify QA clearance of the bulk solution for sterile filtration.
2. Gather materials:
   • Pre-sterilized 0.22 µm filter (PVDF or PES membrane)
   • Sterile hoses, clamps, and connectors
   • Integrity tester (calibrated)
3. Ensure filtration assembly is performed in a Grade A/B environment.
4. Record filter lot number, expiry date, and serial number in Annexure-1.

5.2 Pre-Use Integrity Test (Optional)

1. If required by product-specific validation, perform pre-use Bubble Point Test or Diffusion Test.
2. Record test results in Annexure-2. Proceed only if filter passes.

5.3 Filtration Process

1. Connect feed vessel to filter inlet and sterile final container to filter outlet using sterile transfer lines.
2. Prime the filter slowly with bulk solution to avoid air entrapment.
3. Begin filtration at pressure ≤ 2.5 bar. Avoid backpressure buildup.
4. Monitor flow rate and collect filtrate into sterile hold vessels or bags.
5. Ensure filtration is completed in one continuous process (no filter change).

5.4 Post-Use Integrity Test

1. Immediately after filtration, disconnect the filter and connect to integrity tester.
2. Perform either Bubble Point, Diffusion Flow, or Pressure Hold Test per filter manufacturer’s specification.
3. Acceptable limits should be as per filter validation protocol.
4. Document results in Annexure-2. Product is considered sterile only if filter passes integrity test.

5.5 Labeling and Documentation

1. Label final bulk container with:
   • Product name
   • Batch number
   • Filtration date/time
   • Storage condition (e.g., 2–8°C)
2. Attach completed filter sterilization log to the BMR and submit to QA for review.

5.6 Deviation Handling

1. In case of filter failure during post-use integrity test:
   • Quarantine the batch
   • Initiate deviation report (Annexure-3)
   • Perform root cause analysis and retest backup samples

6. Abbreviations

• BMR: Batch Manufacturing Record
• QA: Quality Assurance
• PES: Polyethersulfone
• PVDF: Polyvinylidene Difluoride

7. Documents

1. Filter Details Log – Annexure-1
2. Integrity Test Report – Annexure-2
3. Deviation Form – Annexure-3

8. References

• ICH Q8 – Pharmaceutical Development
• FDA Guidance for Industry: Sterile Drug Products by Aseptic Processing
• PDA Technical Report No. 26 – Sterilizing Filtration of Liquids

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Filter Details Log

Annexure-2: Integrity Test Report

Annexure-3: Deviation Form

Revision History:

Standard Operating Procedure for Product Contact Surface Management in Biosimilar Manufacturing

1. Purpose

To establish a GMP-compliant procedure for the management, cleaning, inspection, and maintenance of product contact surfaces used in biosimilar manufacturing to ensure product integrity and safety.

2. Scope

This SOP applies to all vessels, tubing, fittings, and components that come into direct contact with biosimilar drug substance or intermediates during production, purification, or storage operations.

3. Responsibilities

• Production: Execute cleaning and inspection of contact surfaces per batch requirement.
• Engineering: Maintain integrity and surface finish of contact equipment.
• QA: Review cleaning logs and surface inspection records; ensure compliance with cleaning validation.

4. Accountability

The Head of Manufacturing and Head of Engineering are jointly accountable for the control and validation of all product contact surfaces in compliance with GMP standards.

5. Procedure

5.1 Identification of Product Contact Surfaces

1. List all parts of equipment and accessories that contact product or buffer solutions including:
   • Stainless steel vessels (grade 316L)
   • Tubing (silicone, TPE)
   • Filter housings, gaskets, sampling valves
2. Update product contact component register (Annexure-1).

5.2 Cleaning and Sanitization

1. Use validated cleaning procedures for each equipment type post-use.
2. For stainless steel: perform CIP with alkaline/acid detergents followed by WFI rinses.
3. For single-use systems: ensure visual cleanliness and proper disposal post-use.

5.3 Visual and Surface Integrity Checks

1. Perform visual inspection under white light for:
   • Scratches, pitting, discoloration
   • Signs of corrosion or damage
2. Perform boroscope examination for internal surfaces annually or post-cleaning validation failure.
3. Record findings in Annexure-2.

5.4 Surface Roughness and Passivation

1. Confirm surface finish of stainless steel parts is Ra ≤ 0.5 µm.
2. Perform passivation (e.g., with nitric or citric acid) every 12 months or post-maintenance.
3. Document passivation activity and results in Annexure-3.

5.5 Labeling and Status Management

1. Label all equipment and parts post-cleaning as “CLEANED – PRODUCT CONTACT” with:
   • Date of cleaning
   • Time and initials
   • Next due date for cleaning/inspection

5.6 Deviation and Requalification

1. Report damage or non-conformance to QA and Engineering immediately.
2. Requalify surface integrity post-repair, maintenance, or replacement before reuse.

6. Abbreviations

• CIP: Clean-in-Place
• Ra: Surface Roughness Average
• QA: Quality Assurance
• WFI: Water for Injection

7. Documents

1. Product Contact Component Register – Annexure-1
2. Surface Inspection Checklist – Annexure-2
3. Passivation Record – Annexure-3

8. References

• ASME BPE Standards for Bioprocessing Equipment
• FDA Guidance on Equipment Cleaning and Maintenance
• WHO TRS 999 – GMP Guidelines for Biotherapeutics

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Product Contact Component Register

Annexure-2: Surface Inspection Checklist

Annexure-3: Passivation Record

Revision History:

Standard Operating Procedure for Hold Vessel Cleaning and Sterilization in Biosimilar Manufacturing

1. Purpose

To establish a GMP-compliant procedure for cleaning and sterilizing stainless steel or single-use hold vessels used for biosimilar drug substance storage, ensuring microbial and chemical cleanliness prior to use.

2. Scope

This SOP applies to all portable and fixed hold vessels used in downstream processing and purified bulk storage areas within biosimilar manufacturing operations.

3. Responsibilities

• Manufacturing Operator: Execute cleaning and sterilization procedures as per batch and equipment log.
• Maintenance: Ensure integrity and calibration of steam sterilization or CIP/SIP systems.
• QA: Review cleaning records and validate cleanliness status before batch use.

4. Accountability

The Head of Manufacturing and Head of QA are accountable for compliance with cleaning validation, sanitation schedules, and preventive maintenance of hold vessels.

5. Procedure

5.1 Pre-Cleaning Inspection

1. Visually inspect vessel interiors for any residual product, stains, or foreign material.
2. Ensure all vessel accessories (e.g., gaskets, valves, spray balls) are intact and in validated configuration.

5.2 Cleaning Process

1. Rinse hold vessel with purified water (PW) to remove loose debris.
2. Apply validated cleaning agent (e.g., alkaline detergent) using either manual scrubbing or automated CIP system.
3. Rinse thoroughly with PW followed by WFI (Water for Injection) until rinse water is clear and pH neutral.
4. Collect final rinse sample for TOC (Total Organic Carbon) and conductivity testing (Annexure-1).

5.3 Visual and Analytical Verification

1. Post-cleaning, visually inspect vessel interior under adequate lighting for cleanliness.
2. Record inspection result in Annexure-2 and attach cleaning checklist to equipment logbook.

5.4 Sterilization Process

1. Connect vessel to validated SIP (Steam-In-Place) system or use autoclave (for small vessels).
2. Achieve sterilization temperature (121°C) for defined hold time (e.g., 30 minutes).
3. Monitor and document sterilization parameters (Annexure-3).

5.5 Storage and Status Labeling

1. Once sterilized, apply “CLEANED & STERILE” label with date, time, and initials.
2. Store vessel in designated clean area under covered condition to avoid contamination.

5.6 Hold Time Validation

1. Do not use vessel beyond validated hold time post-sterilization (e.g., 72 hours).
2. If hold time is exceeded, repeat the cleaning and sterilization cycle.

5.7 Deviation Handling

1. In case of failed TOC, microbial load, or visible residue, document deviation and re-clean the vessel.
2. Investigate root cause and log in Annexure-4.

6. Abbreviations

• CIP: Clean-in-Place
• SIP: Steam-in-Place
• WFI: Water for Injection
• TOC: Total Organic Carbon

7. Documents

1. Final Rinse Sample Test Report – Annexure-1
2. Visual Inspection Checklist – Annexure-2
3. Sterilization Cycle Report – Annexure-3
4. Cleaning Deviation Form – Annexure-4

8. References

• ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• WHO GMP Annex 4 – HVAC and Cleanroom Classification
• FDA Guidance on Cleaning Validation

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Final Rinse Sample Test Report

Annexure-2: Visual Inspection Checklist

Annexure-3: Sterilization Cycle Report

Annexure-4: Cleaning Deviation Form

Revision History:

Standard Operating Procedure for Cold-Chain Handling and Transfer of Purified Bulk in Biosimilar Manufacturing

1. Purpose

To establish a validated, GMP-compliant procedure for handling and transferring biosimilar purified bulk drug substance (BDS) under cold-chain conditions to ensure product integrity during internal movement or dispatch to fill-finish facilities.

2. Scope

This SOP applies to all biosimilar purified bulk lots that require storage and transfer at refrigerated (2–8°C) or frozen (≤ –20°C) temperatures during transit between manufacturing, storage, and formulation areas.

3. Responsibilities

• Production: Prepare and hand over purified bulk containers for cold-chain transfer.
• Warehouse/Logistics: Validate cold chain packaging, ensure calibrated temperature monitoring devices, and maintain documentation.
• QA: Approve readiness of consignment and verify records before dispatch.

4. Accountability

The Head of Supply Chain and Head of Quality Assurance are accountable for ensuring cold-chain processes maintain temperature specifications and comply with GMP requirements.

5. Procedure

5.1 Pre-Transfer Preparation

1. Verify bulk product has passed all applicable in-process QC tests and QA release.
2. Confirm labeling on containers includes product ID, batch number, storage condition (e.g., 2–8°C), and status (Released).
3. Select pre-qualified cold boxes, gel packs, or validated passive shippers capable of maintaining temperature for the expected transfer duration.

5.2 Temperature Monitoring Setup

1. Use calibrated data loggers placed at representative locations (e.g., center and periphery of payload).
2. Activate temperature loggers and record device ID and calibration due date in Annexure-1.

5.3 Packaging and Loading

1. Condition refrigerant packs at required temperatures (e.g., 2–8°C or –20°C) for minimum 24 hours prior to use.
2. Assemble shipper per vendor’s packing instruction: refrigerant layer, product containers, buffer pads, and logger placement.
3. Seal shipper with tamper-evident tape and label externally with:
   • “Refrigerated Product – Do Not Freeze”
   • Shipping location
   • Contact person

5.4 Transfer and Handover

1. Transport shipper using clean, qualified trolley or vehicle maintaining recommended temperature range.
2. Ensure transfer is completed within maximum hold time defined in the BMR or validation study.
3. Receiver must verify outer condition, temperature logger status, and document observations in Annexure-2.

5.5 Deviation Handling

1. If temperature excursions are recorded or packaging is compromised:
   • Quarantine affected shipment
   • Initiate deviation form (Annexure-3)
   • QA to assess product impact and disposition

6. Abbreviations

• BDS: Bulk Drug Substance
• GMP: Good Manufacturing Practice
• QA: Quality Assurance
• QC: Quality Control

7. Documents

1. Temperature Logger Activation Log – Annexure-1
2. Cold Chain Transfer Record – Annexure-2
3. Temperature Excursion Report – Annexure-3

8. References

• WHO TRS 961 – Model Guidance on Storage and Transport of Time- and Temperature-Sensitive Products
• ICH Q1A – Stability Testing of New Drug Substances
• FDA Guidance on Transporting Biologic Products

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Temperature Logger Activation Log

Annexure-2: Cold Chain Transfer Record

Annexure-3: Temperature Excursion Report

Revision History:

Standard Operating Procedure for Storage of Purified Bulk Product in Biosimilar Manufacturing

1. Purpose

To define a GMP-compliant procedure for the proper storage of biosimilar purified bulk drug substance (BDS) including labeling, temperature control, documentation, and transfer for further processing or fill-finish operations.

2. Scope

This SOP applies to all batches of biosimilar drug substance that have completed downstream purification and are ready for temporary storage in controlled environments pending release or filling.

3. Responsibilities

• Production: Label, transfer, and store purified bulk in designated areas under controlled conditions.
• Warehouse: Monitor temperature and maintain logbooks of storage units.
• QA: Verify labeling, quarantine status, and approve release from storage.
• QC: Perform hold-time stability sampling if applicable.

4. Accountability

The Head of Manufacturing and Head of Quality Assurance are jointly accountable for ensuring proper storage and traceability of purified bulk material prior to final drug product manufacturing.

5. Procedure

5.1 Transfer from DSP to Storage

1. Ensure purified bulk has passed all in-process checks (e.g., pH, bioburden, conductivity).
2. Transfer bulk in pre-cleaned and validated stainless steel or single-use containers as per batch record.
3. Seal containers with tamper-evident ties and label as per Section 5.2.

5.2 Labeling of Bulk Containers

1. Apply GMP-compliant label with following details:
   • Product name
   • Batch number
   • Quantity/volume
   • Storage temperature range
   • Status: Quarantine / Released
   • Date and time of storage
2. Labels must be water-resistant, legible, and affixed securely.

5.3 Storage Conditions

1. Store bulk in designated refrigerated chamber at 2–8°C or per product-specific conditions.
2. Place on validated stainless steel racks or pallet systems avoiding direct contact with walls or floor.
3. Environmental conditions must be monitored with calibrated sensors and auto-alarms.
4. Log temperature every 30 minutes using electronic data logger (Annexure-1).

5.4 Quarantine and Hold Duration

1. Place bulk under “QUARANTINE” status until QA batch release is completed.
2. Do not use for filling or formulation until QA provides written release.
3. If storage exceeds hold-time limit defined in the stability protocol, raise a deviation.

5.5 Transfer to Fill-Finish or Formulation

1. Release transfer initiated only upon QA clearance.
2. Transfer must follow cold-chain handling SOP (refer SOP/BS/192/2025).
3. Document transfer time, personnel, and destination (Annexure-2).

5.6 Deviation Management

1. Any deviation in storage conditions, labeling error, or temperature excursion must be recorded and investigated.
2. Document deviation in Annexure-3 and report to QA within 2 hours.

6. Abbreviations

• BDS: Bulk Drug Substance
• QA: Quality Assurance
• QC: Quality Control
• GMP: Good Manufacturing Practice

7. Documents

1. Bulk Storage Temperature Log – Annexure-1
2. Bulk Transfer Record – Annexure-2
3. Storage Deviation Form – Annexure-3

8. References

• ICH Q5C – Stability Testing of Biotechnological/Biological Products
• WHO GMP for Biotherapeutic Products
• FDA Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing

9. SOP Version

Version: 2.0

10. Approval Section

11. Annexures

Annexure-1: Bulk Storage Temperature Log

Annexure-2: Bulk Transfer Record

Annexure-3: Storage Deviation Form

Revision History: